Item 8.01. Other Events.
On April 8, 2022, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that the Company has paused enrollment in clinical trials
with BCX9930 while it investigates elevated serum creatinine levels seen in some
patients. Patients currently enrolled in the trials are continuing on study
drug at this time. A copy of the press release is filed as Exhibit 99.1 hereto
and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press release dated April 8, 2022 entitled "BioCryst Pauses
Enrollment in BCX9930 Clinical Trials"
104 Cover Page Interactive Data File (embedded within the Inline
XBRL document)
© Edgar Online, source Glimpses